2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Supportive Care, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Biological Processes, Pathogenesis, Metabolism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Immunology, Immunodeficiency, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4414 The importance of reducing mild-to-moderate infections in secondary immunodeficiency: A discrete-choice experiment among patients with hematological malignancies

Matthew Quaife, PhD, Julia Braverman2, Pedro Garbes3, Chiara Whichello4, Gabriela S Fernandez5, Laura Panattoni6, Quazi Ataher7, Batyrkhan Kuatov8, Joshua A. Hill I, MD9, Sergio Giralt, MD10, Sara Barmettler11
1 PPD Evidera Patient-Centered Research, Thermo Fisher Scientific, London, United Kingdom
2 CSL Behring, King of Prussia, Pennsylvania, United States
3 CSL Behring, Waltham, Massachusetts, United States
4 PPD Evidera Patient-Centered Research, Thermo Fisher Scientific, London, United Kingdom
5 PPD Evidera Patient-Centered Research, Thermo Fisher Scientific, Waltham, Massachusetts, United States
6 PPD Evidera Patient-Centered Research, Thermo Fisher Scientific, Waltham, Massachusetts, United States
7 CSL Behring, King of Prussia, Pennsylvania, United States
8 CSL Behring, Bern, Switzerland
9 Fred Hutchinson Cancer Center, Seattle, Washington, United States
10 Adult Bone Marrow Transplant Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, United States, Department of Medicine, Weill Cornell Medical College, New York, New York, United States
11 Massachusetts General Hospital, Allergy & Clinical Immunology Unit, Boston, Massachusetts, United States

Background: Patients with hematological malignancies and secondary immunodeficiency (SID) experience infections of varying severity. Severe infections requiring hospitalization are highly burdensome and central to decisions about initiating immunoglobulin replacement therapy (IgRT). However, recurrent mild-to-moderate infections are less widely recognized despite their potential to substantially affect patients’ daily lives. This study quantified how patients value reductions in the risk of mild-to-moderate infections relative to avoiding hospitalization and accepting the administration and side-effect burdens of preventative IgRT.

Methods: US adults  with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), multiple myeloma (MM), or non-Hodgkin lymphoma (NHL) who had initiated systemic therapy or were at least 3 months after stem-cell transplantation or chimeric antigen receptor T-cell therapy completed an online discrete-choice experiment. Participants were recruited through physician referrals and databases. In 10 choice tasks, participants chose between two hypothetical preventative IgRT profiles or routine care with oral antibiotics or antivirals. DCE attributes and levels were the number of mild-to-moderate infections managed at home (0, 2, 4, 8, or 12 infections per year), the number of hospitalizations due to severe infections (0, 1, 2, or 4 hospitalizations per year), the annual risk of a mild side effect (0%, 10%, or 20%), and treatment administration (1 hour weekly at home or 3 hours monthly in hospital). Attribute levels were chosen to reflect clinically relevant scenarios using standard DCE development methods, including patient qualitative and cognitive interviews and expert input to ensure realism and relevance. A mixed logit model estimated preference weights, relative attribute importance (RAI), and trade-offs expressed as mild-to-moderate infection equivalents. Preference heterogeneity was explored using interacted mixed-logit models across selected clinical and demographic subgroups.

Results: Among 296 participants, 127 (42.9%) had CLL/SLL, 123 (41.6%) MM, and 46 (15.5%) NHL; mean age was 60.2 years, and 132 (44.6%) were female. All attributes influenced treatment choices. Avoiding hospitalizations due to severe infections was most important (RAI, 50.42%; 95% CI, 46.19%-54.77%), while reducing mild-to-moderate infections followed immediately (36.47%; 95% CI, 32.28%-40.49%). Together, the 2 infection outcomes accounted for 86.9% of total RAI. Avoiding 1 hospitalization was equivalent to avoiding 4.32 mild-to-moderate infections annually (95% CI, 3.74-4.90). After accounting for outcomes and administration characteristics, there was no significant population-average preference for preventative IgRT over routine care or vice versa (estimate: -0.03; 95% CI, -0.52 to 0.46). In subgroup analyses, participants reporting at least 4 mild-to-moderate infections in the previous year placed greater value on avoiding both hospitalization (P<0.001) and future mild-to-moderate infections (P<0.01) than those reporting 0-3 infections. NHL participants valued avoiding hospitalization more than participants with CLL/SLL or MM (both P<0.05). Participants without, or unsure about, a history of low immunoglobulin (P<0.01) or SID due to low immunoglobulin (P<0.05) showed stronger preferences for weekly home administration, while those without or unsure about prior immunoglobulin therapy were more sensitive to mild side-effect risk (P<0.05).

Conclusions: Reducing mild-to-moderate infection risk represented more than one-third of total treatment importance and was the second most important driver of treatment choice after preventing hospitalization. These findings support considering the full spectrum of infection burden, together with individual treatment priorities, when evaluating preventative SID treatments and discussing IgRT with patients.

Pedro Garbes: CSL Behring - Current Employment